22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › Syndax Pharmaceuticals, Inc. › 2024-2025

Syndax Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Syndax Pharmaceuticals, Inc.’s Form 8-K, filed May 16, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 223Asset managers, any item
  • 1,045Fund votes
  • May 14, 2025Meeting date

Results at a glance

Meeting of May 14, 2025: 5 items on Syndax Pharmaceuticals, Inc.’s Form 8-K, filed May 16, 2025: 5 passed (calculated).

Dissent

Significant dissent: 1 director (29.1% against).

Notable dissent: 1 director (19.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Syndax Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Syndax Pharmaceuticals, Inc.

These tallies are Syndax Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 16, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Syndax Pharmaceuticals, Inc. — official shareholder meeting results, meeting held May 14, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Keith A. Katkin 53,552,483---- 12,880,6194,852,212 81%Passed (calculated)—
Elect Director: Dennis G. Podlesak 47,082,144---- 19,350,9584,852,212 71%Passed (calculated)—
Elect Director: Aleksandra Rizo, M.D., Ph.D. 63,139,437---- 3,293,6654,852,212 95%Passed (calculated)—
2. Advisory vote on executive compensation 62,495,0313,829,672108,399 --4,852,212 94%Passed (calculated)—
3. Ratification of selection of independent registered public accounting firm 71,183,10771,90930,298 ---- 99.9%Passed (calculated)—

Source: Syndax Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 16, 2025 — read the filing on EDGAR.

How asset managers voted at the Syndax Pharmaceuticals, Inc. 2024-2025 meeting

223 asset managers disclosed a vote on at least one Syndax Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Aleksandra Rizo, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 63,139,437WITHHELD: 3,293,665
Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: Election of Directors: Aleksandra Rizo, M.D., Ph.D.

Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Aleksandra Rizo, M.D., Ph.D.”): 63,139,437 for, 3,293,665 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 18,131,762 for, 427,120 withheld.

FOR
FOR: 18,131,762WITHHOLD: 427,120
Largest asset managers voting on “Election of Directors: Aleksandra Rizo, M.D., Ph.D.” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,649,4380 00For
BlackRock3,921,2940 00For
Fidelity1,965,0780 00For
State Street1,901,8990 00For
MUTUAL FUND SERIES TRUST1,178,0620 00For
FRANKLIN STRATEGIC SERIES1,165,9270 00For
Charles Schwab693,1270 00For
Dimensional00 0305,130Withhold
Exchange Place Advisors Trust280,5200 00For
JPMorgan233,3780 00For
Goldman Sachs227,7880 00For
Equitable129,9930 083,950Mixed
TIAA200,1970 00For
Delaware/Macquarie180,0000 00For
QUANTITATIVE MASTER SERIES LLC141,0740 00For
Thornburg133,5480 00For
Jackson National96,9670 08,137Mixed
Victory Capital103,8340 00For
Aberdeen99,3400 00For
Lincoln Financial77,8620 00For
AIG/SunAmerica76,8180 00For
Brighthouse61,8460 00For
John Hancock60,9830 00For
Direxion Shares ETF Trust55,8200 00For
ProShares52,5900 00For

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Elect Director: Dennis G. Podlesak

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%WITHHELD
FOR: 47,082,144WITHHELD: 19,350,958
Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: Election of Directors: Dennis G. Podlesak

Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Dennis G. Podlesak”): 47,082,144 for, 19,350,958 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 15,031,697 for, 3,527,185 withheld.

FORWITHHOLD
FOR: 15,031,697WITHHOLD: 3,527,185
Largest asset managers voting on “Election of Directors: Dennis G. Podlesak” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,649,4380 00For
BlackRock3,921,2940 00For
Fidelity1,965,0780 00For
State Street3,2880 01,898,611Withhold
MUTUAL FUND SERIES TRUST1,178,0620 00For
FRANKLIN STRATEGIC SERIES1,165,9270 00For
Charles Schwab693,1270 00For
Dimensional00 0305,130Withhold
Exchange Place Advisors Trust280,5200 00For
JPMorgan233,3780 00For
Goldman Sachs00 0227,788Withhold
Equitable129,9930 083,950Mixed
TIAA200,1970 00For
Delaware/Macquarie00 0180,000Withhold
QUANTITATIVE MASTER SERIES LLC141,0740 00For
Thornburg133,5480 00For
Jackson National00 0105,104Withhold
Victory Capital00 0103,834Withhold
Aberdeen00 099,340Withhold
Lincoln Financial17,0560 060,806Mixed
AIG/SunAmerica00 076,818Withhold
Brighthouse32,0900 029,756Mixed
John Hancock00 060,983Withhold
Direxion Shares ETF Trust00 055,820Withhold
ProShares00 052,590Withhold

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Elect Director: Keith A. Katkin

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD
FOR: 53,552,483WITHHELD: 12,880,619
Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: Election of Directors: Keith A. Katkin

Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Keith A. Katkin”): 53,552,483 for, 12,880,619 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 17,077,965 for, 1,480,917 withheld.

FOR
FOR: 17,077,965WITHHOLD: 1,480,917
Largest asset managers voting on “Election of Directors: Keith A. Katkin” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,649,4380 00For
BlackRock3,921,2940 00For
Fidelity1,965,0780 00For
State Street1,900,0310 01,868For
MUTUAL FUND SERIES TRUST1,178,0620 00For
FRANKLIN STRATEGIC SERIES1,165,9270 00For
Charles Schwab693,1270 00For
Dimensional00 0305,130Withhold
Exchange Place Advisors Trust280,5200 00For
JPMorgan233,3780 00For
Goldman Sachs00 0227,788Withhold
Equitable129,9930 083,950Mixed
TIAA200,1970 00For
Delaware/Macquarie00 0180,000Withhold
QUANTITATIVE MASTER SERIES LLC141,0740 00For
Thornburg133,5480 00For
Jackson National00 0105,104Withhold
Victory Capital00 0103,834Withhold
Aberdeen00 099,340Withhold
Lincoln Financial77,8620 00For
AIG/SunAmerica00 076,818Withhold
Brighthouse32,0900 029,756Mixed
John Hancock00 060,983Withhold
Direxion Shares ETF Trust00 055,820Withhold
ProShares00 052,590Withhold

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Advisory vote on executive compensation

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 11 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 62,495,031AGAINST: 3,829,672

Prior year: 73.9% for (May 15, 2024 meeting) ▲ 20.3 pts

Details: description as filed, official tally, votes by 221 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2025 proxy statement.

Syndax Pharmaceuticals, Inc.’s own tally for this item (“2. Advisory vote on executive compensation”): 62,495,031 for, 3,829,672 against, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 56 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,649,4380 00For
BlackRock3,921,2940 00For
Fidelity1,965,0780 00For
State Street1,901,787112 00For
MUTUAL FUND SERIES TRUST1,178,0620 00For
FRANKLIN STRATEGIC SERIES1,165,9270 00For
Charles Schwab693,1270 00For
Dimensional305,1300 00For
Exchange Place Advisors Trust280,5200 00For
JPMorgan233,3780 00For
Goldman Sachs227,7880 00For
Equitable213,9430 00For
TIAA200,1970 00For
Delaware/Macquarie180,0000 00For
Simplify Exchange Traded Funds148,2170 00For
QUANTITATIVE MASTER SERIES LLC141,0740 00For
Thornburg133,5480 00For
Jackson National105,1040 00For
Victory Capital103,8340 00For
Aberdeen099,340 00Against
Lincoln Financial77,8620 00For
AIG/SunAmerica76,8180 00For
Brighthouse61,8460 00For
John Hancock60,9830 00For
Direxion Shares ETF Trust55,8200 00For

Fund voting reports, all 56 managers: 18,561,659 for, 118,257 against, 22,313 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 181 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Kynam Capital Management, LP7,541,2770 00For
Eversept Partners, LP4,212,2700 00For
State Street3,539,68126,696 00For
BlackRock3,398,9450 00For
GEODE CAPITAL MANAGEMENT, LLC2,024,7840 00For
FRANKLIN ADVISERS INC2,010,6670 00For
Sofinnova Investments, Inc.1,993,7990 00For
Woodline Partners LP1,890,5400 00For
KINGDON CAPITAL MANAGEMENT, L.L.C.1,804,3600 00For
Catalio Capital Management, LP1,537,5870 00For
Point721,249,3530 00For
BNP Paribas Asset Management Holding S.A.01,221,269 00Against
Aisling Capital Management LP1,025,0000 00For
Ensign Peak Advisors, Inc955,2370 00For
PFM Health Sciences, LP926,4240 00For
Avidity Partners Management LP925,0000 00For
SILVERARC CAPITAL MANAGEMENT, LLC755,3040 00For
Octagon Capital Advisors LP751,8190 00For
Two Sigma749,7540 00For
Charles Schwab693,6660 00For
Northern Trust647,4354,549 00For
Saturn V Capital Management LP581,3000 00For
DAFNA Capital Management LLC542,0020 00For
Nantahala Capital Management, LLC524,4970 00For
Exome Asset Management LLC486,6470 00For

Institutional-manager reports, all 181 managers: 47,496,264 for, 2,106,479 against, 1,654 abstained, 292 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of selection of independent registered public accounting firm

Calculated outcomeAUDIT-RELATEDPassed (calculated)

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 71,183,107AGAINST: 71,909

Prior year: 99.6% for (May 15, 2024 meeting) ▲ 0.3 pts

Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

Syndax Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of selection of independent registered public accounting firm”): 71,183,107 for, 71,909 against, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the shares present or represented, the standard stated in the company’s proxy statement: votes for exceeded votes against plus abstentions.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Syndax Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 148,217 for, 19,775 withheld).

The 54 asset managers below reported 18,528,101 for, 1,461 against, 22,313 abstained.

FOR
FOR: 18,528,101AGAINST: 1,461ABSTAIN: 22,313
Largest asset managers voting on “TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard4,649,4380 00For
BlackRock3,921,2940 00For
Fidelity1,965,0780 00For
State Street1,901,787112 00For
MUTUAL FUND SERIES TRUST1,178,0620 00For
FRANKLIN STRATEGIC SERIES1,165,9270 00For
Charles Schwab693,1270 00For
Dimensional305,1300 00For
Exchange Place Advisors Trust280,5200 00For
JPMorgan233,3780 00For
Goldman Sachs227,7880 00For
Equitable213,9430 00For
TIAA200,1970 00For
Delaware/Macquarie180,0000 00For
QUANTITATIVE MASTER SERIES LLC141,0740 00For
Thornburg133,5480 00For
Jackson National105,1040 00For
Victory Capital103,8340 00For
Aberdeen99,3400 00For
Lincoln Financial77,8620 00For
AIG/SunAmerica76,8180 00For
Brighthouse61,8460 00For
John Hancock60,9830 00For
Direxion Shares ETF Trust55,8200 00For
ProShares52,5900 00For

Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).

Largest Syndax Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 86,047,032 shares outstanding at the time of that meeting.

Fund voting reports: top Syndax Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 5.40%
2BlackRock 4.56%
3Fidelity 2.28%
4State Street 2.21%
5MUTUAL FUND SERIES TRUST 1.37%
6FRANKLIN STRATEGIC SERIES 1.35%
7Charles Schwab 0.81%
8Dimensional 0.35%
9Exchange Place Advisors Trust 0.33%
10JPMorgan 0.27%
Institutional-manager reports: top Syndax Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Kynam Capital Management, LP 8.76%
2Eversept Partners, LP 4.90%
3State Street 4.14%
4BlackRock 3.95%
5GEODE CAPITAL MANAGEMENT, LLC 2.35%
6FRANKLIN ADVISERS INC 2.34%
7Sofinnova Investments, Inc. 2.32%
8Woodline Partners LP 2.20%
9KINGDON CAPITAL MANAGEMENT, L.L.C. 2.10%
10Catalio Capital Management, LP 1.79%

Reported Syndax Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Syndax Pharmaceuticals, Inc. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with BlackRock, Inc.8,787,650 10.21%Proxy statement (DEF 14A), proxy filed April 1, 2025
BlackRock8,542,251 9.93%Form 13F, quarter ended March 31, 2025
Entities affiliated with Kynam Capital Management, LP8,520,000 9.90%Proxy statement (DEF 14A), proxy filed April 1, 2025
Kynam Capital Management, LP8,520,000 9.90%Schedule 13G, filed February 14, 2025
Vanguard Group4,871,065 5.66%Form 13F, quarter ended March 31, 2025
Point724,208,700 4.89%Form 13F, quarter ended March 31, 2025
State Street3,971,732 4.62%Form 13F, quarter ended March 31, 2025
Goldman Sachs3,921,541 4.56%Form 13F, quarter ended March 31, 2025
Citadel Advisors3,021,482 3.51%Form 13F, quarter ended March 31, 2025
Morgan Stanley2,281,916 2.65%Form 13F, quarter ended March 31, 2025

Percentages above are of 86,047,032 shares outstanding, as reported by Syndax Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Syndax Pharmaceuticals, Inc.'s shareholder meeting held May 14, 2025, in the 2024-2025 proxy season, 223 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,045 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Syndax Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 16, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Syndax Pharmaceuticals, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Syndax Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “Syndax Pharmaceuticals (SNDX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/syndax-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.